Literature DB >> 16018789

Cancer risk of patients with ischaemic syndromes.

S K Pehrsson1, A Linnersjö, N Hammar.   

Abstract

INTRODUCTION: Angiogenesis constitutes the regulation of collateral formation in subjects with ischaemic syndromes and is also a prerequisite for cancer progression. Patients with severe symptomatic ischaemic syndromes may have a reduced ability for angiogenesis and thus a lower risk to develop cancer. SUBJECTS AND METHODS: Patients below 80 years and treated for acute myocardial infarction (AMI), angina pectoris (AP), intermittent claudication (IC) or undergoing revascularization during 1972-1991 in Stockholm county (n=63 921) were followed regarding cancer incidence 1972-2000. Cancer incidence was compared with that of the general population of Stockholm County by standardized incidence ratios (SIR).
RESULTS: An increased incidence of cancer overall compared with the general population was seen in patients treated for AMI [SIR men 1.08 (95% Confidence Interval 1.04-1.11) and women 1.15 (1.09-1.21)], AP [men 1.16 (1.11-1.21) and women 1.06 (1.00-1.12)] and IC [men 1.48 (1.31-1.64) and women 1.43 (1.17-1.68)]. This increase was mainly due to an increased incidence of tobacco-related cancer. In patients undergoing revascularization no increase in incidence was seen [SIR men 0.97 (0.91-1.03) and women 1.06 (0.91-1.20)].
CONCLUSION: Patients with mild to moderate symptomatic ischaemic syndromes are, as expected, at increased risk of subsequently develop tobacco-related cancer. A lack of increased cancer risk in patients undergoing revascularization could be due to a reduced ability for angiogenesis in patients with severe atherosclerotic disease but may also be related to lifestyle changes.

Entities:  

Mesh:

Year:  2005        PMID: 16018789     DOI: 10.1111/j.1365-2796.2005.01518.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  6 in total

1.  Intima-media thickness, myocardial perfusion and laboratory risk factors of atherosclerosis in patients with breast cancer treated with anthracycline-based chemotherapy.

Authors:  Hana Kalábová; Bohuslav Melichar; Leoš Ungermann; Jiří Doležal; Lenka Krčmová; Markéta Kašparová; Jiří Plíšek; Radomír Hyšpler; Miroslav Pecka; Dagmar Solichová
Journal:  Med Oncol       Date:  2010-06-22       Impact factor: 3.064

2.  Myocardial infarction and future risk of cancer in the general population-the Tromsø Study.

Authors:  Ludvig B Rinde; Birgit Småbrekke; Erin M Hald; Ellen E Brodin; Inger Njølstad; Ellisiv B Mathiesen; Maja-Lisa Løchen; Tom Wilsgaard; Sigrid K Brækkan; Anders Vik; John-Bjarne Hansen
Journal:  Eur J Epidemiol       Date:  2017-02-07       Impact factor: 8.082

3.  Increased cancer risk after myocardial infarction: fact or fiction? A systemic review and meta-analysis.

Authors:  Na Li; Zhigang Huang; Yanda Zhang; Haitao Sun; Jiamei Wang; Jian Zhao
Journal:  Cancer Manag Res       Date:  2019-03-01       Impact factor: 3.989

4.  Peripheral arterial disease and systematic detection of circulating tumor cells: rationale and design of the DETECTOR prospective cohort study.

Authors:  Alexandra Yannoutsos; Manon Fontaine; Alexandre Galloula; Diane Damotte; Gilles Chatellier; Patrizia Paterlini-Bréchot; Guy Meyer; Jean Pastre; Véronique Duchatelle; Valéria Marini; Karl-Léo Schwering; Isabelle Lazareth; Parinaz Ghaffari; Audrey Stansal; Hélène Sanson; Cécile Labrousse; Hélène Beaussier; Nesrine Ben Nasr; Marc Zins; Sergio Salmeron; Emmanuel Messas; Jean-Patrick Lajonchère; Joseph Emmerich; Pascal Priollet; Jean Trédaniel
Journal:  BMC Cardiovasc Disord       Date:  2019-09-13       Impact factor: 2.298

5.  Risk Factors for Cancer Mortality in Spain: Population-Based Cohort Study.

Authors:  Antonio D Lázaro-Sánchez; Asunción Juárez Marroquí; Jose Antonio Quesada Rico; Domingo Orozco-Beltrán
Journal:  Int J Environ Res Public Health       Date:  2022-08-10       Impact factor: 4.614

6.  Incidence of new onset cancer in patients with a myocardial infarction - a nationwide cohort study.

Authors:  Morten Malmborg; Christine Benn Christiansen; Michelle D Schmiegelow; Christian Torp-Pedersen; Gunnar Gislason; Morten Schou
Journal:  BMC Cardiovasc Disord       Date:  2018-10-22       Impact factor: 2.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.